Context: Higher serum TSH levels, both within the reference range and in those with subclinical hypothyroidism (SCH), have been associated with increased risk of atherosclerosis and cardiovascular (CV) events in a number of cross-sectional and longitudinal studies.
Introduction
Subclinical hypothyroidism (SCH), a state of mild thyroid failure characterised by a raised serum thyroid stimulating hormone (TSH) level with normal thyroid hormone concentrations, is associated with increased risk of cardiovascular disease (CVD) and CVD-related mortality 1 . Furthermore, higher TSH levels within the reference range are associated with an increased risk of myocardial infarction in patients with established cardiovascular disease 2 . In addition, there is growing evidence that CVD patients with SCH have increased cardiac and all-cause mortality 3, 4 . SCH has been associated with lipid abnormalities, atherosclerotic plaque progression and instability and endothelial dysfunction 5 . However, the association of thyroid dysfunction after non-ST elevation acute coronary syndrome (NSTE-ACS) with blood thrombogenicity (BT) is unknown. We hypothesized that in the setting of NSTE-ACS, the presence of SCH increases blood thrombogenicity.
Materials
Patients: Patients with symptoms of myocardial ischaemia and elevated high sensitive cardiac troponin I levels (>0.1 μmol/L) on at least 2 occasions 12 hours apart and angiographically proven coronary artery disease (>50% stenosis in at least one major vessel) were recruited. In accordance with the current American Heart Association/European Society of Cardiology guidelines on NSTE-ACS management, all patients received 300mg loading and 75 mg daily maintenance dose of both aspirin and clopidogrel along with other three standard secondary prevention medications: hydoxymethyl co-enzyme A reductase inhibitor (HMG-CoA), angiotensin converting enzyme (ACE) inhibitor (or angiotensin receptor blocker) and a beta-blocker (or a calcium channel blocker as clinically indicated) 6, 7 . This study was approved by the Local Research Ethics Committee and all participants gave written informed consent. The study was conducted in accordance with the ethical principles of the declaration of Helsinki.
Exclusion criteria: Patients with normal coronary angiogram, current smokers, those on antiplatelet or antithrombotic agents other than aspirin and clopidogrel, individuals with known thyroid dysfunction or on medications known to affect thyroid function such as amiodarone or lithium, coagulation abnormalities, anaemia (Hb<12g/dl), and those with malignancy or being investigated for malignancy were excluded.
Assessment of platelet dependent thrombus formation: This was assessed 7 to 10 days after the index event using the validated ex-vivo Badimon perfusion chamber were measured by electrochemiluminescence immunoassay on the Roche cobas e602 (Roche Diagnostics, UK). P selectin and soluble CD40L were measured by ELISA methods (R&D systems, Abington,UK) and TNF alfa was measured by electrochemiluminescence methods (MSD, MD,USA). The within-day and between day co-efficient of variation for all tests were less than 5%.
Patients with serum TSH above the reference range and serum free T4 levels within the reference range were classed as having SCH (n=12) whereas those with both TSH and free T4 within the reference range were categorised as being euthyroid (n=58). In addition, to ensure that the serum TSH abnormality was not transient, individuals with SCH had their levels rechecked a few months after their NSTE-ACS (median 4, range 2 -14 months). This showed that 9 of 12 individuals were still in the SCH state, one person with the highest TSH of 23 mU/L had been commenced on levothyroxine, one person had not had their thyroid function rechecked and one participant's TSH had reverted back to within the reference range. None of the patients had overt hypothyroidism (FT4 < 9 pmol/L), hyperthyroidism (both overt and subclinical), nor had a low free T3 level.
Statistical analysis: Patients with SCH were compared to euthyroid individuals using unpaired t-test. Variables that were not normally distributed (serum TSH levels and thrombus area) were log transformed to normality prior to analysis. A multivariate regression analysis was performed with thrombus area as the dependent and established CV risk factors (age, gender, history of prior CVD, diabetes mellitus, hypertension, cerebrovascular disease, body mass index and LDL cholesterol levels) and serum TSH as independent variables. Secondary analyses utilising SCH as a categorical variable or FT4 or FT3 concentrations as a linear variable were also performed. Analyses were performed using SPSS version 21.0 (IBM Corp, NY, USA). Two-tailed significance was set at <0.05.
Results

Baseline Characteristics:
SCH was identified in12 (17%) post NSTE-ACS patients. Baseline demographic, clinical, risk factor profile and laboratory characteristics were similar in both the SCH and euthyroid groups (Table 1) Figure 1 .
Predictors of thrombus area:
Serum TSH level as a continuous variable was an independent predictor of thrombus area (β=0.30, p=0.01). Figure 2 (for web only) shows univariate association between serum TSH and thrombus area. Neither FT4 nor FT3 concentrations were found to have any independent association with total thrombus area (results not shown).
In secondary analysis, SCH was an independent predictor of thrombus area (β=0.25, (10,902) in euthyroid group; p=0.08.
Discussion
Higher blood thrombogenicity was related to increasing serum TSH levels which was significant in patients with SCH when compared to the euthyroid group despite all patients receiving optimal secondary prevention therapy including aggressive antithrombotic therapy. In addition, SCH was a significant predictor of thrombus burden independent of other well established cardiovascular risk factors such as diabetes mellitus and cerebrovascular disease. This finding may explain the higher cardiovascular risk seen in the SCH population. Moreover, the linear relationship between serum TSH and thrombus area in the post NSTE-ACS setting suggesting that the association may have a causal link although appropriately powered intervention studies alone will prove this. This study also demonstrates that prevalence of SCH in a carefully selected population is high in patients post NSTE-ACS (17%).
SCH has been associated with many CV risk factors such as increased serum lipid levels, diastolic hypertension, impaired endothelial function, increased arterial stiffness, and possibly altered coagulation parameters and elevated C-reactive protein levels 5 . The Rotterdam study suggested that SCH is independently associated with atherosclerosis and with an increased incidence of myocardial infarction in the aging female population 9 . Recent meta-analyses have also confirmed higher CV events and mortality in younger to middle aged adults with SCH 10, 11 . Furthermore, the 12-year mortality follow up in HUNT study demonstrated that high serum TSH levels within the reference range are associated with increased mortality from coronary heart disease in women , and is associated with a reduced all-cause mortality as well as fewer CVD events in younger individuals 16 . Recently, it has been reported that mean platelet volume, a risk factor for CVD, is higher in SCH individuals and was positively correlated with TSH levels 17 .
As far as we are aware, BT in relation to thyroid function particularly patients with SCH in a post NSTE-ACS state has never been assessed before. The Badimon perfusion chamber system is a validated ex vivo model of vessel injury and thrombosis and has previously been used to evaluate the effects of novel antithrombotic agents in human subjects in different disease states 18, 19 . We have used this perfusion system to evaluate the effects of anti-platelet therapy on thrombus formation in various high risk population groups such as patients with established coronary artery disease and type 2 diabetes mellitus. This technique has been well validated in our laboratory 8, 20 . The model enables the measurement of thrombus formation in native (non-anticoagulated) whole blood triggered by exposure to physiologically relevant substrate (collagen in tunica media), and under different rheological conditions mimicking those in narrowed blood vessels.
Mechanisms that increase the risk of CV events in patients with established CVD and SCH are unknown. Hence our findings are novel and have the potential for further research in this high CV risk population.
The main limitation of our study is its relatively small sample size particularly in the SCH group. Despite this, the SCH group were found to have a higher thrombus area independent of other traditional risk factors. Furthermore, we found a linear relationship between serum TSH levels and thrombus area that adds to the growing evidence relating to a link between the two. The other limitation of this study, due to its observational nature, is that causality of thyroid status with higher thrombus burden cannot be assessed. In addition, it is unknown if higher thrombus burden is associated with increased future CV events. Finally, due to the carefully selected nature of participants for this study (exclusion of current smokers, those with anaemia, etc; outlined in detail in Methods), the results of this study may not be generalised to the wider SCH population post NSTE-ACS. For instance, smokers tend to have a lower serum TSH levels but have a higher CVD risk.
In conclusion, this study has shown that post NSTE-ACS individuals with higher serum TSH levels and, in particular SCH, have higher thrombus burden despite optimal secondary prevention therapy which may explain their high CV risk. Abbreviations: BMI, body mass index; CVD, cardiovascular disease; CVA, cerebrovascular accident; hs CRP, high-sensitivity C-reactive protein; LDL, low density lipoprotein; TPO, thyroid peroxidase; sCD40L, soluble CD40 ligand; TNFalfa, tumour necrosis factor alfa. 
